- Sputnik International
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

Trump Promises to Fast-Track Approval for Regeneron's COVID-19 Drug

© REUTERS / Jonathan ErnstUS President Donald Trump
US President Donald Trump - Sputnik International
A week ago, the US president was admitted to the Walter Reed Medical Centre for treatment after announcing that he had tested positive for COVID-19.

US President Donald Trump has said in a radio interview with Rush Limbaugh that he is pushing to get COVID-19 antibody drugs developed by Regeneron Pharmaceuticals Inc and Eli Lilly and Co approved quickly and out to hospitals after his own treatment.

Trump stated that he might not have recovered without the therapeutics he received to combat his own COVID-19 illness.

"Now I am free, I feel perfect, I am not taking anything. I am off", Trump told radio anchor Rush Limbaugh.

The US president added that earlier in the day, he met 11 administering doctors who showed him "amazing stats".

The statement comes after Trump announced that he and First Lady Melania Trump had contracted COVID-19. The US president was admitted to hospital on 2 October for treatment and was released on 5 October to continue recovering at the White House.

Trump was treated with the remdesivir antiviral treatment, an 8-gramme dose of Regeneron's polyclonal antibody cocktail, and the steroid drug dexamethasone.

U.S. President Donald Trump makes an announcement about his treatment for coronavirus disease (COVID-19), in Washington, U.S., in this still image taken from video, October 7, 2020. - Sputnik International
Trump to Return to Campaign Trail if Doctor Declares Him Fit From COVID-19 Bout
Initially developed by US manufacturer Gilead Sciences as an Ebola drug, remdesivir has shown a positive effect in treating SARS and MERS. In May, the US Food and Drug Administration issued an authorisation for the emergency use of remdesivir to treat patients hospitalised with COVID-19.

A COVID-19 patient usually needs a five-day treatment course of six vials of remdesivir.

In July, the US biotechnology company Regeneron won a $450 million contract to mass-produce up to 300,000 doses of a drug to treat COVID-19.

According to the company, its COVID-19 investigational anti-viral antibody treatment, REGN-COV2, consists of two antibodies cloned from mice with their immune systems genetically altered to mimic humans. The drug is undergoing advanced clinical trials for two possible uses - to treat COVID-19 infections and to prevent the disease, Regeneron said.

To participate in the discussion
log in or register
Заголовок открываемого материала